Organon plans third-quarter filing on October 19 for Organon stock

Published on 10/20/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organon Q2 revenue fell 2.30 percent to USD 1.56 billion. Organon stock costs EUR 12.26 on October 20, 2026 at 7:07 p.m. CEST after hours.

Filing plan and financial picture

Organon planned its third-quarter 2026 Form 10-Q filing on October 19, 2026.
Second-quarter 2026 revenue fell 2.30 percent year over year to USD 1.56 billion.
Organon stock costs EUR 12.26 at Lang & Schwarz on October 20, 2026 at 7:07 p.m. CEST.
Organon's market capitalization was USD 3.6 billion and its P/E was 17.88 as of October 20, 2026.

OGN, US68622V1061, Illustration mit AI erstellt.

Organon planned to report its third-quarter 2026 results through a Form 10-Q filing after announcing the plan on October 19, 2026, according to Organon. The company also said it would file a Form 8-K with non-GAAP reconciliations and had suspended its quarterly earnings calls while its proposed Sun Pharma acquisition remains pending. Organon stock was trading at EUR 12.26 at Lang & Schwarz on October 20, 2026 at 7:07 p.m. CEST, after the Xetra close.

Filing plan sets the near-term date

The October 19 announcement points investors toward the next regulatory disclosure rather than an earnings call. Organon said the quarter ended September 30, 2026 and that the results had not been finalized, so the filing remains the key date for updated revenue, earnings and non-GAAP information.

The company also stated that it did not currently expect milestone expense in the third quarter of 2026. That disclosure matters because milestone costs can affect the relationship between GAAP results and the adjusted figures Organon plans to provide in its Form 8-K.

Second-quarter revenue fell 2.30 percent

Organon reported revenue of USD 1.56 billion for the second quarter of 2026, down 2.30 percent from the same quarter a year earlier, according to DataPorium. The same period produced net income of USD 108.0 million and diluted earnings per share of USD 0.40, giving investors a concrete baseline for the third-quarter filing.

For comparison, revenue had reached USD 1.46 billion in the first quarter of 2026. The sequential increase to USD 1.56 billion was 6.71 percent, while net income declined from USD 146.0 million to USD 108.0 million, a 26.03 percent decrease.

Stock stays near its yearly high

On the NYSE, Organon was last at USD 13.77 on October 20, 2026 at 1:14 p.m. EDT. Its 52-week range was USD 5.69 to USD 13.83 as of that date, placing the price 0.43 percent below the high. The market capitalization was USD 3.6 billion.

Valuation and reporting dates

Organon's P/E was 17.88 as of October 20, 2026, while its dividend yield was 1.00 percent. MarketBeat estimated November 9, 2026 as the third-quarter reporting date and November 5, 2026 as the conference-call date, although Organon's filing announcement said quarterly earnings calls were suspended during the pending transaction.

What the filing can clarify

The next report will show whether the second-quarter revenue decline continued through September 30, 2026 and whether the absence of expected milestone expense supports adjusted profitability. It will also give investors the first detailed update on the company's portfolio of more than 70 products across women's health, biosimilars and established medicines since the October 19 filing plan.

Organon stock and the next filing

Organon stock was trading at EUR 12.26 at Lang & Schwarz on October 20, 2026 at 7:07 p.m. CEST. The next major company-specific reference point is the planned third-quarter Form 10-Q disclosure, with the estimated reporting date of November 9, 2026.

The further course of trading is shown by the continuously updated real-time quote of Organon stock.